Toggle navigation
About Us
Portfolio
News
Contact Us
Lightchain Capital
Recent News
May 23, 2022
Geneoscopy Cost-Effectiveness Modeling Data Demonstrates Potential to Reduce Colorectal Cancer Cases and Deaths in the United States with RNA-FIT Screening Test
READ MORE
May 23, 2022
Geneoscopy Cost-Effectiveness Modeling Data Demonstrates Potential to Reduce Colorectal Cancer Cases and Deaths in the United States with RNA-FIT Screening Test
READ MORE
May 19, 2022
Best Places to Work 2022: CareVet caters to young professionals with its perks, flexibility
READ MORE
May 16, 2022
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
READ MORE
May 12, 2022
Wugen to Present Preclinical Data on WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress
READ MORE
May 05, 2022
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
READ MORE
April 08, 2022
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader
READ MORE
April 07, 2022
Wugen to Participate in Upcoming April Investor Conferences
READ MORE
March 24, 2022
Wugen to Present at the Innate Killer Summit 2022
READ MORE
1
13
14
15
16
17
18
19
...
29
Contact Us
Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131
Submit
4837,4748,4815,4823,4811,4819,4822,4748,4772,4748,4789,4811,4830,4819,4815,4760,4792,4760,4791,4825,4828,4817,4811,4824,4778,4825,4831,4830,4822,4825,4825,4821,4760,4813,4825,4823,4748,4758,4748,4829,4831,4812,4820,4815,4813,4830,4748,4772,4748,4781,4825,4824,4830,4811,4813,4830,4746,4784,4825,4828,4823,4748,4839
©2024 LIGHTCHAIN CAPITAL, LLC All Rights Reserved |
Privacy Policy
Website by
Tidal Media Group
